NO20004431L - Glysintransportinhibitorer - Google Patents

Glysintransportinhibitorer

Info

Publication number
NO20004431L
NO20004431L NO20004431A NO20004431A NO20004431L NO 20004431 L NO20004431 L NO 20004431L NO 20004431 A NO20004431 A NO 20004431A NO 20004431 A NO20004431 A NO 20004431A NO 20004431 L NO20004431 L NO 20004431L
Authority
NO
Norway
Prior art keywords
epsi
epilepsy
piperazinyl
piperidinyl
fluorophenyl
Prior art date
Application number
NO20004431A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004431D0 (no
Inventor
Walter Herman Maria Lou Luyten
Frans Eduard Janssens
Ludo Edmond Josephine Kennis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20004431D0 publication Critical patent/NO20004431D0/no
Publication of NO20004431L publication Critical patent/NO20004431L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20004431A 1998-03-06 2000-09-05 Glysintransportinhibitorer NO20004431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98200701 1998-03-06
PCT/EP1999/001309 WO1999044596A2 (en) 1998-03-06 1999-02-26 Glycine transport inhibitors

Publications (2)

Publication Number Publication Date
NO20004431D0 NO20004431D0 (no) 2000-09-05
NO20004431L true NO20004431L (no) 2000-10-30

Family

ID=8233444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004431A NO20004431L (no) 1998-03-06 2000-09-05 Glysintransportinhibitorer

Country Status (17)

Country Link
EP (1) EP1059922A2 (xx)
JP (1) JP2002505277A (xx)
KR (1) KR20010032968A (xx)
CN (1) CN1292698A (xx)
AU (1) AU3408999A (xx)
BG (1) BG104685A (xx)
BR (1) BR9907951A (xx)
CA (1) CA2322164A1 (xx)
EE (1) EE200000482A (xx)
HR (1) HRP20000523A2 (xx)
HU (1) HUP0101048A2 (xx)
IL (1) IL138228A0 (xx)
NO (1) NO20004431L (xx)
PL (1) PL343435A1 (xx)
SK (1) SK13082000A3 (xx)
TR (1) TR200002567T2 (xx)
WO (1) WO1999044596A2 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515392A (en) * 1999-06-28 2004-03-26 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
CA2406652A1 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7049343B2 (en) 2000-09-08 2006-05-23 Merck & Co., Inc. Substituted hydrazine derivatives
CA2422044A1 (en) * 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
AR032653A1 (es) 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
DK1703909T3 (da) 2003-09-09 2009-06-22 Hoffmann La Roche 1-benzoyl-piperazinderivater som glycinoptagelsesinhibitorer til behandling af psykoser
RU2354653C2 (ru) * 2003-09-09 2009-05-10 Ф.Хоффманн-Ля Рош Аг Производные 1-(2-аминобензол)пиперазина, используемые в качестве ингибиторов поглощения глицина и предназначенные для лечения психоза
WO2005058885A2 (en) * 2003-12-18 2005-06-30 Glaxo Group Limited Piperidine derivatives and their use as glycine transporter inhibitors
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
AU2005313581B2 (en) 2004-12-09 2011-06-09 F. Hoffmann-La Roche Ag Phenyl-piperazin methanone derivatives
KR100883003B1 (ko) * 2004-12-15 2009-02-12 에프. 호프만-라 로슈 아게 알츠하이머병의 치료를 위한 글라이신 수송체1(ｇｌｙｔ-1) 억제제로서 바이- 및 트라이사이클릭 치환된페닐 메탄온
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
BRPI0519744A2 (pt) * 2005-01-06 2009-03-10 Hoffmann La Roche metanonas de fenila substituÍda por sulfanila como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distérbios neurolàgicos e neuropsiquiÁtricos
CA2593463C (en) * 2005-01-07 2013-10-08 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
EP1843767B1 (en) 2005-01-18 2009-07-08 F. Hoffmann-Roche AG 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders.
AU2006208547B2 (en) 2005-01-26 2011-02-10 F. Hoffmann-La Roche Ag Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
CA2596636C (en) * 2005-02-07 2016-04-12 F. Hoffmann-La Roche Ag Heterocyclyl substituted phenyl methanones as inhibitors of the glycine transporter 1
CN100341871C (zh) * 2005-06-03 2007-10-10 复旦大学 含哌啶结构的有机硫化合物，制备方法和应用
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2008053352A2 (en) * 2006-11-01 2008-05-08 Purdue Pharma L.P. Phenylpropionamide compounds and the use thereof
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2707305A1 (en) * 2007-12-12 2009-06-18 Amgen Inc. Glycine transporter-1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140119A (en) * 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
AU1041599A (en) * 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives

Also Published As

Publication number Publication date
KR20010032968A (ko) 2001-04-25
PL343435A1 (en) 2001-08-13
HUP0101048A2 (hu) 2001-10-28
CA2322164A1 (en) 1999-09-10
EE200000482A (et) 2002-02-15
BG104685A (en) 2001-04-30
BR9907951A (pt) 2001-01-30
TR200002567T2 (tr) 2000-11-21
JP2002505277A (ja) 2002-02-19
NO20004431D0 (no) 2000-09-05
AU3408999A (en) 1999-09-20
SK13082000A3 (sk) 2001-03-12
HRP20000523A2 (en) 2001-02-28
CN1292698A (zh) 2001-04-25
IL138228A0 (en) 2001-10-31
EP1059922A2 (en) 2000-12-20
WO1999044596A3 (en) 2000-02-17
WO1999044596A2 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
NO20004431L (no) Glysintransportinhibitorer
NO20004432L (no) Glysintransportinhibitorer
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BG108860A (en) BICYCLIC AMINO ACIDS, PHARMACEUTICAL COMPOSITION, AND THE USE OF THEM
DE60037139D1 (de) Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
AP2004002952A0 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds.
MXPA04003245A (es) Hidroxipropilaminas.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
DE59900222D1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
DE60204046D1 (de) N-heterocyclylhydrazide als neurotrophe mittel
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto
NO993126D0 (no) Anvendelse av benzoylalkyl-1,2,3,6-tetrahydropyridiner
ATE347893T1 (de) Triazepin-derivate als neurotrope mittel
DE602004019133D1 (de) Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
DE602004008796D1 (de) VERWENDUNG VON 1,3-DIAZADIBENZOÄe,hÜ AZULENEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN FORMULIERUNGEN FÜR DIE BEHANDLUNG UND PRÄVENTION VON ERKRANKUNGEN UND STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application